CNVI — Conavi Medical Income Statement
0.000.00%
Last trade - 00:00- CA$17.26m
- CA$31.83m
- CA$23.79m
Annual income statement for Conavi Medical, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | fx Final |
| Revenue | |||||
| Total Revenue | 0 | 26.8 | 25.2 | 0 | 23.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 79.2 | 19.5 | 64 | 61.3 | 15.5 |
| Operating Profit | -79.2 | 7.32 | -38.8 | -61.3 | 8.33 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -55.6 | -32.4 | -18.6 | -55.4 | 9.41 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -55.6 | -32.4 | -18.6 | -55.4 | 9.38 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -55.6 | -32.4 | -18.6 | -55.4 | 9.38 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -55.6 | -32.4 | -18.6 | -55.4 | 9.38 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.81 | -0.533 | -0.172 | -0.479 | 0.11 |